Aptose Biosciences (NASDAQ:APTO) (TSE:APS) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01, Fidelity Earnings reports.
Shares of NASDAQ APTO traded down $0.08 during midday trading on Wednesday, hitting $2.26. The stock had a trading volume of 40,795 shares, compared to its average volume of 404,058. The firm’s 50 day moving average is $2.59. The stock has a market cap of $133.05 million, a P/E ratio of -2.58 and a beta of 1.61. Aptose Biosciences has a 52 week low of $1.57 and a 52 week high of $3.20. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 0.09.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Monday, May 13th. HC Wainwright restated a “buy” rating and issued a $6.00 price objective (down previously from $8.50) on shares of Aptose Biosciences in a report on Wednesday. Finally, Roth Capital restated a “buy” rating on shares of Aptose Biosciences in a report on Thursday, May 23rd. Seven research analysts have rated the stock with a buy rating, Aptose Biosciences currently has a consensus rating of “Buy” and a consensus price target of $5.25.
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Further Reading: Quiet Period Expirations Explained
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.